1734 — Sinphar Pharmaceutical Co Balance Sheet
0.000.00%
Last trade - 00:00
- TWD5.85bn
- TWD7.03bn
- TWD2.86bn
- 55
- 31
- 39
- 33
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 975 | 886 | 1,194 | 1,245 | 1,244 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 572 | 635 | 469 | 593 | 685 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 2,122 | 2,262 | 2,540 | 2,703 | 2,778 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3,384 | 3,352 | 3,321 | 3,247 | 3,204 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 5,878 | 5,917 | 6,127 | 6,221 | 6,185 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 889 | 1,156 | 1,330 | 1,534 | 1,446 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 2,952 | 3,133 | 3,382 | 3,499 | 3,255 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 2,926 | 2,783 | 2,744 | 2,722 | 2,930 |
Total Liabilities & Shareholders' Equity | 5,878 | 5,917 | 6,127 | 6,221 | 6,185 |
Total Common Shares Outstanding |